WO2004042031A3 - Safer attenuated virus vaccines with missing or diminished latency of infection - Google Patents

Safer attenuated virus vaccines with missing or diminished latency of infection Download PDF

Info

Publication number
WO2004042031A3
WO2004042031A3 PCT/US2003/035167 US0335167W WO2004042031A3 WO 2004042031 A3 WO2004042031 A3 WO 2004042031A3 US 0335167 W US0335167 W US 0335167W WO 2004042031 A3 WO2004042031 A3 WO 2004042031A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
latency
virus
infection
live
Prior art date
Application number
PCT/US2003/035167
Other languages
French (fr)
Other versions
WO2004042031A2 (en
Inventor
Jeffrey Irvine Cohen
Edward Michael Cox
Lesley M Pesnicak
Original Assignee
Us Gov Health & Human Serv
Jeffrey Irvine Cohen
Edward Michael Cox
Lesley M Pesnicak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Jeffrey Irvine Cohen, Edward Michael Cox, Lesley M Pesnicak filed Critical Us Gov Health & Human Serv
Priority to AU2003295398A priority Critical patent/AU2003295398A1/en
Publication of WO2004042031A2 publication Critical patent/WO2004042031A2/en
Publication of WO2004042031A3 publication Critical patent/WO2004042031A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Abstract

Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the varicella zoster virus. Deletion of a significant portion from both copies of the varicella zoster gene ORF63 was shown to inhibit establishment of a latent infection from a live vaccine form of the virus. Other desirable viral antigen encoding sequence(s) and/or cytokine genes advantageously may replace deleted genetic material to enhance a desired immunological response. Aspects of the discovery pertain to live vaccines of other viruses, and can provide a variety of vaccines having greater safety.
PCT/US2003/035167 2002-11-05 2003-11-05 Safer attenuated virus vaccines with missing or diminished latency of infection WO2004042031A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003295398A AU2003295398A1 (en) 2002-11-05 2003-11-05 Safer attenuated virus vaccines with missing or diminished latency of infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42360302P 2002-11-05 2002-11-05
US60/423,603 2002-11-05

Publications (2)

Publication Number Publication Date
WO2004042031A2 WO2004042031A2 (en) 2004-05-21
WO2004042031A3 true WO2004042031A3 (en) 2004-09-16

Family

ID=32312687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035167 WO2004042031A2 (en) 2002-11-05 2003-11-05 Safer attenuated virus vaccines with missing or diminished latency of infection

Country Status (2)

Country Link
AU (1) AU2003295398A1 (en)
WO (1) WO2004042031A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012092A2 (en) * 2004-06-29 2006-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Safer attenuated virus vaccines with missing or diminished latency of infection
US10166285B2 (en) 2006-11-09 2019-01-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant virus with diminished latency and methods of using same
CN101967466A (en) 2009-07-28 2011-02-09 新泽西医学院 ORF7 auxotrophic varicella virus strain, vaccine containing same and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985615A (en) * 1974-03-12 1976-10-12 Research Foundation For Microbial Diseases Of Osaka University Process for preparing live varicella vaccines
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985615A (en) * 1974-03-12 1976-10-12 Research Foundation For Microbial Diseases Of Osaka University Process for preparing live varicella vaccines
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines

Also Published As

Publication number Publication date
AU2003295398A8 (en) 2004-06-07
WO2004042031A2 (en) 2004-05-21
AU2003295398A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
Bachmann et al. Recall proliferation potential of memory CD8+ T cells and antiviral protection
Rühl et al. Vaccination against the Epstein–Barr virus
JP5065024B2 (en) TC-83 derived alphavirus vectors, particles and methods
Small et al. Viruses—From pathogens to vaccine carriers
WO2003092592A3 (en) Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
DE69842165D1 (en) PREPARATION OF ATTENUATED PARAIN FLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES
Le Nouën et al. Attenuation of human respiratory viruses by synonymous genome recoding
RU2003103779A (en) EXPRESSION SYSTEM
Sun et al. The status and prospects of Epstein–Barr virus prophylactic vaccine development
YU37502A (en) Infectious clones
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
Ma et al. Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae
WO2002000169A3 (en) Production of vaccines using transgenic plants
WO2006012092A3 (en) Safer attenuated virus vaccines with missing or diminished latency of infection
WO2010128338A2 (en) Vaccines
WO2004042031A3 (en) Safer attenuated virus vaccines with missing or diminished latency of infection
WO2004106360A3 (en) Viral vectors with improved properties
WO2000022137A3 (en) Selectively replicating viral vectors
EP1523333A4 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
ATE494377T1 (en) VACCINES AGAINST IPNV THAT ARE ISOLATED FROM Yeast CELLS
DK8789A (en) PROCEDURE FOR THE PREPARATION OF MODIFIED, STRICTLY DEFINED RNA VIRUS STEMS AND VACCINE AND ITS USE
WO1995003399A3 (en) Production method for preparation of disabled viruses
WO1994000586A3 (en) Infectious bovine rhinotracheitis virus mutants and vaccines
EP1427443A4 (en) Vaccine using papilloma virus e proteins delivered by viral vector

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP